4,163 reports of this reaction
1.5% of all DENOSUMAB reports
#13 most reported adverse reaction
MYALGIA is the #13 most commonly reported adverse reaction for DENOSUMAB, manufactured by Amgen, Inc. There are 4,163 FDA adverse event reports linking DENOSUMAB to MYALGIA. This represents approximately 1.5% of all 278,448 adverse event reports for this drug.
Patients taking DENOSUMAB who experience myalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYALGIA is a less commonly reported adverse event for DENOSUMAB, but still significant enough to appear in the safety profile.
In addition to myalgia, the following adverse reactions have been reported for DENOSUMAB:
The following drugs have also been linked to myalgia in FDA adverse event reports:
MYALGIA has been reported as an adverse event in 4,163 FDA reports for DENOSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYALGIA accounts for approximately 1.5% of all adverse event reports for DENOSUMAB, making it a notable side effect.
If you experience myalgia while taking DENOSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.